From psychedelic medicine to AI-powered neuroscience and personalized nutrition, the future of health is taking shape.
Lilly Bets on Psychedlics
Eli Lilly is acquiring AtaiBeckley in a deal worth up to $3.8B, marking the largest acquisition in psychedelic medicine to date.
- The deal gives Lilly access to BPL-003, an intranasal DMT therapy now entering Phase 3 trials for treatment-resistant depression, along with a broader pipeline of psychedelic therapies.
- The acquisition follows recent moves by AbbVie and Otsuka, growing federal support for psychedelic research, and mounting clinical evidence around next-generation mental health treatments.
Once considered fringe science, psychedelic medicine is rapidly becoming a strategic priority for Big Pharma.
As traditional antidepressants reach their limits, the next frontier may focus less on managing symptoms and more on rewiring the brain.
Wonder Raises $650M
Food technology company Wonder closed a $650M Series D at a $9B valuation to accelerate expansion, robotics, and artificial intelligence.
Founded by Marc Lore, Wonder is building a vertically integrated food platform spanning chef-created restaurants, delivery, meal kits, and AI-powered personalization.
Since its last funding round, the company has nearly tripled its footprint to 140 locations as it builds the infrastructure for personalized food — where AI, logistics, and health data converge to shape what people eat every day.
Hemispheric Taps AI to Decode the Human Brain
Emerging from stealth with $52M in funding, Hemispheric unveiled Descartes, a foundation AI model trained to interpret brain activity.
What: Built on more than 250K hours of EEG and behavioral data collected from 100K participants, the platform aims to create objective tests for conditions including depression, PTSD, Alzheimer’s disease, and traumatic brain injury.
How: Patients complete a 15-minute EEG assessment designed to help clinicians diagnose disease, personalize treatment, and monitor progress.
The implication: As AI transforms imaging, genomics, and diagnostics, companies are building foundational brain models to power the future of precision mental health care.
